Viral Latency and Reactivation: How Dormant Viruses Cause Disease.

Manisha Desai*

Microbiology Division, Tata Institute of Fundamental Research, India

Introduction

Viral latency is a unique strategy employed by certain viruses to evade the immune system and persist in the host for extended periods without causing active infection. During latency, viruses remain dormant within host cells, often for years or even decades, without being detected by the immune system. However, under certain conditions, these dormant viruses can reactivate, leading to disease. The phenomenon of viral latency and reactivation poses significant challenges in the treatment and management of viral infections. This article explores the mechanisms of viral latency, factors that trigger reactivation, and the diseases associated with this process [1].

Viral latency refers to the ability of a virus to enter a dormant state within a host cell, where it ceases to replicate but maintains the potential to reactivate under certain conditions. During latency, the virus hides from the host's immune system by minimizing the expression of viral proteins that could otherwise trigger an immune response. Many viruses, including herpesviruses (such as herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus) and HIV, have evolved the ability to establish latency. In this state, the virus remains in specific tissues, often in a small subset of cells, such as neurons or immune cells [2].

To establish latency, viruses often integrate their genetic material into the host cell's DNA or exist as episomes within the cell's nucleus. Herpesviruses, for example, establish latency by maintaining their genome as circular episomes within neurons or immune cells, where viral gene expression is minimal. HIV, on the other hand, integrates its genetic material into the host's genome, where it remains hidden from the immune system. By entering a dormant state, latent viruses are able to evade immune detection, allowing them to persist in the host indefinitely. This mechanism ensures the virus's survival and ability to reactivate when conditions become favourable [3].

Reactivation occurs when latent viruses resume replication and become active again. This process is often triggered by various stressors, including immunosuppression, physical or emotional stress, fever, or exposure to ultraviolet (UV) light. During reactivation, the virus begins to replicate, producing new viral particles that can lead to active infection and disease. For example, the varicella-zoster virus, which causes chickenpox, can remain dormant in nerve cells and later reactivate to cause shingles, a painful condition affecting older adults or those with weakened immune systems. Viral reactivation can also result in the transmission of the virus to others, as is often seen with herpes simplex virus [4].

Herpesviruses are among the most well-known viruses capable of latency and reactivation. Once a person is infected with a herpesvirus, the virus remains in their body for life. Herpes simplex virus (HSV) type 1 and type 2 are responsible for oral and genital herpes, respectively. After the initial infection, HSV enters sensory neurons, where it establishes latency. Reactivation can occur intermittently, resulting in the recurrence of cold sores or genital lesions. Similarly, the Epstein-Barr virus (EBV), which causes infectious mononucleosis, establishes latency in B cells and can reactivate to contribute to the development of certain cancers, such as Burkitt's lymphoma [5].

HIV latency is a major barrier to curing HIV/AIDS. Following infection, HIV integrates its genome into the DNA of host cells, particularly CD4+ T cells. While antiretroviral therapy (ART) can effectively suppress viral replication and prevent disease progression, it cannot eliminate latent HIV reservoirs. As a result, the virus can persist in a dormant state for years, undetected by the immune system. If ART is interrupted, HIV can reactivate and resume replication, leading to viral rebound and disease progression. Current research efforts are focused on finding ways to eliminate these latent reservoirs, which is key to achieving a functional cure for HIV [6].

The varicella-zoster virus (VZV) is another herpesvirus that can establish latency and later reactivate. VZV causes chickenpox during primary infection, after which the virus remains dormant in the sensory neurons of the dorsal root ganglia. In later life, particularly in individuals with weakened immune systems, VZV can reactivate, causing shingles, also known as herpes zoster. Shingles is characterized by painful skin rashes and nerve pain, and in some cases, it can lead to long-term complications such as postherpetic neuralgia. The availability of a shingles vaccine has reduced the incidence of VZV reactivation in older adults [7].

A variety of factors can trigger the reactivation of latent viruses. Immunosuppression, whether due to HIV infection, cancer chemotherapy, organ transplantation, or aging, is a major factor in reactivation, as it weakens the host's ability to control latent viruses. Physical and emotional stress, exposure to UV light, and illness (such as a fever) can also promote viral reactivation. In the case of herpesviruses, reactivation is often

***Correspondence to:** Manisha Desai, Microbiology Division, Tata Institute of Fundamental Research, India, E-mail: manisha.desai@email.com

***Received:** 10-Oct-2024, Manuscript No. AAMCR-24-155098; **Editor assigned:** 11-Oct-2024, PreQC No. AAMCR-24-155098 (PQ); **Reviewed:** 22-Oct-2024, QC No. AAMCR-24-155098; **Revised:** 24-Oct-2024, Manuscript No. AAMCR-24-155098 (R); **Published:** 31-Oct-2024, DOI: 10.35841/aamcr-8.5.233*

***Citation:** Desai M. Viral Latency and Reactivation: How Dormant Viruses Cause Disease. J Micro Bio Curr Res. 2024;8(5):233*

linked to periods of increased stress, when the immune system is less effective at suppressing viral replication. Identifying these triggers is important for preventing reactivation and managing associated diseases [8].

Viral reactivation can lead to a range of diseases, depending on the virus and the host's immune status. In immunocompetent individuals, reactivation may cause mild or localized symptoms, such as cold sores or shingles. However, in immunocompromised individuals, reactivation can result in more severe outcomes, including widespread infections, organ damage, or the development of virus-associated cancers. For example, reactivation of Epstein-Barr virus in immunocompromised patients can lead to lymphoproliferative disorders, while cytomegalovirus (CMV) reactivation in transplant recipients can cause life-threatening complications, such as pneumonia or organ rejection [9].

Managing viral latency and reactivation presents a significant challenge in clinical practice. Antiviral drugs, such as acyclovir for herpesviruses, can suppress viral replication and reduce the severity of symptoms during reactivation, but they do not eliminate latent viruses. In the case of HIV, lifelong antiretroviral therapy is necessary to prevent viral replication and progression to AIDS, but it cannot clear latent reservoirs. Researchers are exploring strategies such as "shock and kill" or "block and lock" approaches to activate latent viruses for elimination or to prevent reactivation altogether. Vaccines, such as the shingles vaccine, also play a role in reducing the risk of reactivation in certain populations [10].

Conclusion

The study of viral latency and reactivation continues to be an important area of research, with implications for treating chronic viral infections and preventing disease. Understanding the molecular mechanisms that govern latency, as well as the host factors that contribute to reactivation, is critical for developing new therapies. Advances in gene-editing technologies, such as CRISPR, offer the potential to target and eliminate latent viral genomes. Additionally, ongoing research into therapeutic vaccines aims to boost the immune system's ability to control latent infections. Ultimately, better strategies for managing viral latency will improve outcomes for individuals affected by chronic viral diseases.

References

1. Brown GD, Denning DW, Gow NA, et al. Hidden Killers: Human fungal infections. Sci Transl Med. 2012;4(165):165rv13.
2. Moyes DL, Wilson D, Richardson JP, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature. 2016;532(7597):64-8.
3. Hardison SE, Brown GD. C-type lectin receptors orchestrate antifungal immunity . Nat Immunol. 2012;13(9):817-22.
4. de Sousa MD, Belda Jr W, Spina R, et al. Topical application of imiquimod as a treatment for chromoblastomycosis . Clin Infect Dis. 2014;58(12):1734-7.
5. Biteen JS, Goley ED, Shapiro L, et al. Three?dimensional super resolution imaging of the midplane protein FtsZ in live Caulobacter crescentus cells using astigmatism. Chem Phys Chem. 2012;13(4):1007-12.
6. Lyu Z, Coltharp C, Yang X, et al. Influence of FtsZ GTPase activity and concentration on nanoscale Z ring structure in vivo revealed by three dimensional Superresolution imaging. Biopolymers. 2016;105(10):725-34.
7. Eswaramoorthy P, Erb ML, Gregory JA, et al. Cellular architecture mediates DivIVA ultrastructure and regulates min activity in Bacillus subtilis. mBio. 2011;2(6):e00257-11.
8. Buss J, Coltharp C, Huang T, et al. In vivo organization of the FtsZ?ring by ZapA and ZapB revealed by quantitative super resolution microscopy . Mol Microbiol. 2013;89(6):1099-120.
9. Buss J, Coltharp C, Shtengel G, et al. A multi-layered protein network stabilizes the Escherichia coli FtsZ-ring and modulates constriction dynamics . PLoS Genet. 2015;11(4):e1005128.
10. Barton MB, Keane TJ, Gadalla T, et al. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol. 1992;23(3):137-43.

Citation: *Desai M. Viral Latency and Reactivation: How Dormant Viruses Cause Disease. J Micro Bio Curr Res. 2024;8(5):233*